Morgan Stanley’s Hepion Pharmaceuticals HEPA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-30
| Closed | -$13 | – | 8180 |
|
|
2025
Q1 | $13 | Buy |
30
+3
| +11% | +$29 | ﹤0.01% | 8002 |
|
|
2024
Q4 | $637 | Hold |
27
| – | – | ﹤0.01% | 7319 |
|
|
2024
Q3 | $909 | Hold |
27
| – | – | ﹤0.01% | 7230 |
|
|
2024
Q2 | $1.38K | Hold |
27
| – | – | ﹤0.01% | 7116 |
|
|
2024
Q1 | $3.38K | Sell |
27
-31
| -53% | -$3.56K | ﹤0.01% | 6980 |
|
|
2023
Q4 | $9.36K | Sell |
58
-204
| -78% | -$38.6K | ﹤0.01% | 6843 |
|
|
2023
Q3 | $65.3K | Sell |
262
-205
| -44% | -$76.5K | ﹤0.01% | 6056 |
|
|
2023
Q2 | $245K | Buy |
467
+379
| +431% | +$233K | ﹤0.01% | 5553 |
|
|
2023
Q1 | $68.5K | Buy |
88
+8
| +10% | +$5.91K | ﹤0.01% | 6155 |
|
|
2022
Q4 | $24.1K | Buy |
80
+63
| +371% | +$26.6K | ﹤0.01% | 6606 |
|
|
2022
Q3 | $8K | Sell |
17
-9
| -35% | -$5.5K | ﹤0.01% | 7146 |
|
|
2022
Q2 | $15K | Sell |
26
-12
| -32% | -$9.99K | ﹤0.01% | 7095 |
|
|
2022
Q1 | $48K | Buy |
38
+1
| +3% | +$1.1K | ﹤0.01% | 6721 |
|
|
2021
Q4 | $42K | Buy |
37
+2
| +6% | +$2.74K | ﹤0.01% | 6894 |
|
|
2021
Q3 | $54K | Sell |
35
-56
| -62% | -$89.7K | ﹤0.01% | 6682 |
|
|
2021
Q2 | $180K | Buy |
+91
| New | +$166K | ﹤0.01% | 6069 |
|
|
2021
Q1 | – | Sell |
-6
| Closed | -$13.2K | – | 7513 |
|
|
2020
Q4 | $14K | Buy |
+6
| New | +$15.5K | ﹤0.01% | 6548 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 6773 |
|
|
2020
Q2 | – | Sell |
-1
| Closed | -$1.91K | – | 6648 |
|
|
2020
Q1 | $1K | Sell |
1
-3
| -75% | -$12K | ﹤0.01% | 6459 |
|
|
2019
Q4 | $19K | Buy |
+4
| New | +$15.5K | ﹤0.01% | 6110 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6679 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6537 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6513 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6414 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6443 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6008 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6191 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6010 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | -$307K | – | 5871 |
|
|
2017
Q2 | $172K | Buy |
+1
| New | +$497K | ﹤0.01% | 5413 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 4844 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 5138 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 4915 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 4827 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 4728 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 4699 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 4746 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 4459 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 5026 |
|
Other funds holding HEPA
Morgan Stanley's HEPA Position: Q2 2025 in Review
Morgan Stanley sold out of Hepion Pharmaceuticals (HEPA) in Q2 2025, closing a stake of 30 shares — an estimated $13 sold.
Morgan Stanley first reported a position in HEPA in Q2 2017 and held it in 20 quarters. The position peaked at $245K in Q2 2023. 4 funds tracked by Wall St. Rank hold HEPA as of Q2 2025.
- Morgan Stanley reported no remaining Hepion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Morgan Stanley sold 30 Hepion Pharmaceuticals shares in Q2 2025, an estimated $13.
- Morgan Stanley first reported a position in Hepion Pharmaceuticals in Q2 2017 and held it in 20 quarters.
- Morgan Stanley's Hepion Pharmaceuticals position peaked at $245K in Q2 2023.
- 4 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2025.
Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.